Literature DB >> 25858058

The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.

Godfrey L Smith1, Niall MacQuaide2.   

Abstract

Entities:  

Keywords:  Editorials; flecainide; heart; polymorphic catecholergic ventricular tachycardia; ryanodine receptor calcium release channel; sarcoplasmic reticulum

Mesh：

Substances：

Year:  2015        PMID： 25858058     DOI： 10.1161/CIRCRESAHA.115.306298

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  12 in total

Review 1.  Therapeutic Strategies Targeting Inherited Cardiomyopathies.

Authors:  Kenneth Varian; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2017-08

2.  Reply from Pei-Chi Yang, Jonathan D. Moreno, Mao-Tsuen Jeng, Xander H. T. Wehrens, Sergei Noskov and Colleen E. Clancy.

Authors:  Pei-Chi Yang; Jonathan D Moreno; Mao-Tsuen Jeng; Xander H T Wehrens; Sergei Noskov; Colleen E Clancy
Journal:  J Physiol       Date:  2016-11-01       Impact factor: 5.182

3.  The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Krystien Vv Lieve; Arthur A Wilde; Christian van der Werf
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 4.  Investigational antiarrhythmic agents: promising drugs in early clinical development.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Dobromir Dobrev
Journal:  Expert Opin Investig Drugs       Date:  2017-07-20       Impact factor: 6.206

5.  Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.

Authors:  Mark D Levin; Sulagna C Saitta; Karen W Gripp; Tara L Wenger; Jaya Ganesh; Jennifer M Kalish; Michael R Epstein; Rosemarie Smith; Richard J Czosek; Stephanie M Ware; Paula Goldenberg; Angela Myers; Kathryn C Chatfield; Matthew J Gillespie; Elaine H Zackai; Angela E Lin
Journal:  Am J Med Genet A       Date:  2018-07-28       Impact factor: 2.802

Review 6.  Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.

Authors:  Samantha C Salvage; Karthik H Chandrasekharan; Kamalan Jeevaratnam; Angela F Dulhunty; Andrew J Thompson; Antony P Jackson; Christopher L-H Huang
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

7.  Is the Debate on the Flecainide Action on the RYR2 in CPVT Closed?

Authors:  Jean-Pierre Benitah; Ana M Gómez
Journal:  Circ Res       Date:  2021-02-04       Impact factor: 17.367

8.  A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.

Authors:  Marcela K Preininger; Rajneesh Jha; Joshua T Maxwell; Qingling Wu; Monalisa Singh; Bo Wang; Aarti Dalal; Zachary T Mceachin; Wilfried Rossoll; Chadwick M Hales; Peter S Fischbach; Mary B Wagner; Chunhui Xu
Journal:  Dis Model Mech       Date:  2016-08-04       Impact factor: 5.758

Review 9.  Catecholaminergic polymorphic ventricular tachycardia: An exciting new era.

Authors:  Shashank P Behere; Steven N Weindling
Journal:  Ann Pediatr Cardiol       Date:  2016 May-Aug

10.  Antiarrhythmic Effects of Carvedilol and Flecainide in Cardiomyocytes Derived from Catecholaminergic Polymorphic Ventricular Tachycardia Patients.

Authors:  R P Pölönen; K Penttinen; H Swan; K Aalto-Setälä
Journal:  Stem Cells Int       Date:  2018-04-12       Impact factor: 5.443
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.